JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

YKL-40 Level and Hypertension Incidence: A Population-Based Nested Case-Control Study in China.

BACKGROUND: Human cartilage glycoprotein-39 (YKL-40) has been suggested to be a new marker of inflammation, atherosclerosis, and endothelial dysfunction. However, whether a higher level of YKL-40 is an independent risk factor for hypertension incidence is still unknown.

METHODS AND RESULTS: In a nested case-control study within a prospective cohort of 12 423 initially healthy Chinese adults, we measured baseline plasma concentrations of YKL-40 among 700 new-onset hypertension cases and 700 age- and sex-matched controls. Multiple conditional logistic regression analyses were used to calculate the odds ratios (95% CIs) of hypertension associated with higher levels of YKL-40 both in the total population and in the age- (>55 and ≤55 years) and sex-matched subgroups. Among the total population, YKL-40 levels were not associated with hypertension risk. In the subgroup older than 55 years, odds ratios (95% CIs) of hypertension for those in the two higher tertiles of YKL-40 were 1.23 (0.77-1.97) and 1.59 (0.99-2.55) (P for linear trend=0.05). In the male subgroup, odds ratios (95% CIs) of hypertension for those in the two higher tertiles of YKL-40 were 1.55 (0.88-2.72) and 2.09 (1.14-3.82) (P for linear trend=0.02). An interaction effect was observed between YKL-40 and sex (P for interaction <0.01) but not between YKL-40 and age (P for interaction=0.21). High YKL-40 level significantly increased hypertension risk in men but decreased hypertension risk with a trend although not significant in women.

CONCLUSIONS: This study suggests that YKL-40 is associated with hypertension incidence only among men. The study findings need to be further verified by prospective cohort studies or clinical trials.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app